APA (7th ed.) Citation

Loibl, S., Schneeweiss, A., & Sinn, P. (2014). PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. Journal of clinical oncology, 32(29), . https://doi.org/10.1200/JCO.2014.55.7876

Chicago Style (17th ed.) Citation

Loibl, Sibylle, Andreas Schneeweiss, and Peter Sinn. "PIK3CA Mutations Are Associated with Lower Rates of Pathologic Complete Response to Anti-human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-overexpressing Breast Cancer." Journal of Clinical Oncology 32, no. 29 (2014). https://doi.org/10.1200/JCO.2014.55.7876.

MLA (9th ed.) Citation

Loibl, Sibylle, et al. "PIK3CA Mutations Are Associated with Lower Rates of Pathologic Complete Response to Anti-human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-overexpressing Breast Cancer." Journal of Clinical Oncology, vol. 32, no. 29, 2014, https://doi.org/10.1200/JCO.2014.55.7876.